Carcinoma, Hepatocellular: all 3,251 studies

Page 16 of 33. Open to participants first (976), then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid TumorsTerminatedNCT05757492Phase 1
• Evaluation of Proteome Multimarker Panel With Multiple Reaction Monitoring as a Surveillance for Hepatocellular CarcinomaActive, not recruitingNCT05756699
• FMT in IT-refractory HCC - FAB-HCC Pilot StudyCompletedNCT05750030Phase 2
• HCC Staging Modified by Tumor MicronecrosisCompletedNCT05739110
• Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic PatientsStatus unknownNCT05738772
• Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular CarcinomaStatus unknownNCT05738447Phase 1
• The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency AblationCompletedNCT05732181Not applicable
• PAtient-PHYsician Relationship AssessmentCompletedNCT05729230
• Domvanalimab and Zimberelimab in Advanced Liver CancersActive, not recruitingNCT05724563Phase 2
• Study on Screening, Verification and Intervention of High-risk Patients With Liver CancerStatus unknownNCT05721300Not applicable
• ALBI and PALBI Scores and HCC PrognosisCompletedNCT05720195
• Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNCT05718882Not applicable
• Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic PatientsStatus unknownNCT05716620
• Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular CarcinomaTerminatedNCT05705791Not applicable
• SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruitingNCT05701488Phase 1
• Non-contrast Abbreviated MRI for Secondary Surveillance of HCCCompletedNCT05690451
• Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver CarcinomaCompletedNCT05681234Not applicable
• Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune MicroenvironmentStatus unknownNCT05677724
• A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB PatientsStatus unknownNCT05671315Not applicable
• Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular CarcinomaStatus unknownNCT05670561Phase 4
• GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method)Status unknownNCT05668793
• Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP ElectrodesActive, not recruitingNCT05666271
• Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyCompletedNCT05665348Phase 2/3
• Alternative Surveillance Program for Patients With High Risk Group of HCCActive, not recruitingNCT05657249Not applicable
• Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular CarcinomaStatus unknownNCT05654896Phase 3
• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT05651022Phase 1/2
• Peri-operative Vitamin D Therapy for HepatectomyStatus unknownNCT05650151Not applicable
• Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular CarcinomaCompletedNCT05643833
• Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT05643391Not applicable
• Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)WithdrawnNCT05641922Not applicable
• Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world StudyStatus unknownNCT05638438
• Artificial Intelligence and Hepatocellular CarcinomaActive, not recruitingNCT05637788
• Effect of Nutritional Indices on the Prognosis of HCC PatientsCompletedNCT05635279
• Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular CarcinomaStatus unknownNCT05631613
• Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T CellsWithdrawnNCT05628545Phase 1/2
• Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein InvasionCompletedNCT05625893Phase 2
• Dose-escalation of Regorafenib in Advanced Hepatocellular CarcinomaActive, not recruitingNCT05622136Phase 2
• Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver FunctionsCompletedNCT05622071Phase 2
• HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicable
• Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving ImmunotherapyStatus unknownNCT05620004Phase 1/2
• Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular CarcinomaStatus unknownNCT05617430Phase 2
• I-FIGS Feasibility StudyCompletedNCT05616039Not applicable
• Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral EtiologiesActive, not recruitingNCT05613621
• Blood Salvage in Orthotopic Liver Transplantation With HCCActive, not recruitingNCT05612477Not applicable
• KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)SuspendedNCT05603572Phase 1/2
• A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05603039Phase 1/2
• Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I StudyStatus unknownNCT05598060Not applicable
• A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular CarcinomaActive, not recruitingNCT05595473Phase 1/2
• Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTTWithdrawnNCT05592197Not applicable
• HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCCStatus unknownNCT05582278Phase 2
• Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation ProceduresTerminatedNCT05582018Not applicable
• PET / MR With PSMA for Diagnosis and Staging of Hepatocellular CarcinomaStatus unknownNCT05580835Not applicable
• Anatomical Radiofrequency Ablation for Small Hepatocellular CarcinomaStatus unknownNCT05580224Not applicable
• AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)Status unknownNCT05578430Phase 2
• Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver TransplantationStatus unknownNCT05576909Phase 2
• The Utility of Cell-free Methylation Markers in Blood for Hepatocellular CarcinomaStatus unknownNCT05576571
• Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular CarcinomaStatus unknownNCT05575622
• The Utility of Cell-free DNA Methylation Markers for Hepatocellular CarcinomaStatus unknownNCT05573217
• Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular CarcinomaWithdrawnNCT05564338Phase 3
• 89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsTerminatedNCT05563272Phase 2
• Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3
• A Real World Study of Regogfinib in HCCStatus unknownNCT05557656
• TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Phase 2
• TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver CancerStatus unknownNCT05550025Phase 2
• Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCCActive, not recruitingNCT05546879Phase 1
• Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 ResectionActive, not recruitingNCT05546619Not applicable
• Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceStatus unknownNCT05545124Phase 2
• Predictive Model for Pain After TACECompletedNCT05545046
• Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCCStatus unknownNCT05544253Phase 2/3
• Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)Status unknownNCT05543304
• Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular CarcinomaCompletedNCT05540925
• Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05536427Phase 1
• TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTTCompletedNCT05535998
• HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCCCompletedNCT05532319Phase 2
• Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTTStatus unknownNCT05530785Not applicable
• Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)Active, not recruitingNCT05520099
• Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib TreatmentCompletedNCT05517239Phase 2
• Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT05507632Phase 2
• Ablation of Hepatocellular Carcinoma: a Nationwide StudyCompletedNCT05498779
• A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC OncogeneTerminatedNCT05497453Phase 1/2
• Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic TumorsCompletedNCT05495529
• HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCCStatus unknownNCT05493332Phase 2
• Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo EmbolizationStatus unknownNCT05491889
• Serum Levels of Some Trace Elements in Hepatocellular Carcinoma PatientsStatus unknownNCT05488587
• Evaluating Novel Therapies in ctDNA Positive GI CancersActive, not recruitingNCT05482516Phase 3
• TACE With Dicycloplatin(TP21) in Unresectable HCCStatus unknownNCT05472896Phase 3
• Neoadjuvant Anti-PD1 in HCCCompletedNCT05471674Phase 2
• Study on the Quality of Life (QoL) After Liver SurgeryCompletedNCT05464706Not applicable
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
• Intra-arterial Perfusion in Interventional RadiologyStatus unknownNCT05458791
• Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular CarcinomaStatus unknownNCT05458115
• Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With AnlotinibStatus unknownNCT05453383Phase 2
• Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.TerminatedNCT05451862Not applicable
• No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet ElectrodesStatus unknownNCT05449873Not applicable
• Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet ElectrodesStatus unknownNCT05449860Not applicable
• Plasma MicroRNA for Prediction of Hepatocellular CarcinomaCompletedNCT05449847
• Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular CarcinomaTerminatedNCT05448677Phase 2
• T-ACE Oil by TAE/TACE in Patients With Hepatocellular CarcinomaTerminatedNCT05435014Phase 1/2
• Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCCActive, not recruitingNCT05433701Not applicable
• A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT05432492Phase 2

← Carcinoma, Hepatocellular overview